[1] Abraham JT, Saint-Cyr M. Keystone and pedicle perforator flaps in reconstructive surgery: New modifications andapplications[J]. Clin Plast Surg, 2017, 44(2):385-402. [2] Kim JT, Kim SW. Perforator flap versus conventionalflap[J]. J Korean Med Sci, 2015, 30(5):514-522. [3] Narushima M, Yamasoba T, Iida T, et al. Pure skin perforator flaps: The anatomical vascularity of the superthin flap[J]. Plast Reconstr Surg, 2018, 142(3):351e-360e. [4] Liang JW, Yu T, Wang X,et al. Free tissue flaps in head and neck reconstruction: Clinical application and analysis of 93 patients of a single institution[J]. Braz J Otorhinolaryngol, 2018, 84(4):416-425. [5] Sethia R, Allarakhia Z, Puram S, et al. Free flap salvage from venous thrombosis by creation of a venocutaneous fistula: Case report and review of the literature[J]. Head Neck, 2019, 41(12):E159-E162. [6] Karakawa R, Harima M, Iida T. Mechanical versus hand-sewn venous anastomoses in free flap reconstruction: A systematic review and meta-analysis[J]. Plast Reconstr Surg, 2019, 143(2):441e-442e. [7] Eltzschig HK, Eckle T. Ischemia and reperfusion: From mechanism to translation[J]. Nat Med, 2011, 17(11):1391-1401. [8] Ballestín A, Casado JG, Abellán E, et al. Ischemia-reperfusion injury in a rat microvascular skin free flap model: A histological, genetic, and blood flow study[J]. PLoS One, 2018, 13(12):e0209624. [9] Tuncer FB, Durmus Kocaaslan FN, Yildirim A, et al. Ischemic preconditioning and iloprost reduces ischemia-reperfusion injury in jejunal flaps: An animal model[J]. Plast Reconstr Surg, 2019, 144(1):124-133. [10] Alam A, Suen KC, Hana Z, et al. Neuroprotection and neurotoxicity in the developing brain: An update on the effects of dexmedetomidine and xenon[J]. Neurotoxicol Teratol, 2017, 60:102-116. [11] Jiang LX, Hu MZ, Lu Y,et al. The protective effects of dexmedetomidine on ischemic brain injury: A meta-analysis[J]. J Clin Anesth, 2017, 40:25-32. [12] Dong J,Guo X, Yang SH, et al. The effects of dexmedetomidine preconditioning on aged rat heart of ischaemia reperfusion injury[J]. Res Vet Sci, 2017, 114:489-492. [13] Sha JC, Zhang HY, Zhao Y, et al. Dexmedetomidine attenuates lipopolysaccharide-induced liver oxidative stress and cell apoptosis in rats by increasing GSK-3β/MKP-1/Nrf2 pathway activity via the α2 adrenergic receptor[J]. Toxicol Appl Pharmacol, 2019, 364:144-152. [14] Chen YP,Feng XJ, Hu XY, et al. Dexmedetomidine ameliorates acute stress-induced kidney injury by attenuating oxidative stress and apoptosis through inhibition of the ROS/JNK signaling pathway[J]. Oxid Med Cell Longev, 2018, 2018:4035310. [15] Jo YY, Kim JY, Lee JY,et al. The effect of intraoperative dexmedetomidine on acute kidney injury after pediatric congenital heart surgery: A prospective randomized trial[J]. Medicine, 2017, 96(28):e7480. [16] Chiu YH, Chang DH,Perng CK. Vascular complications and free flap salvage in head and neck reconstructive surgery: Analysis of 150 cases of reexploration[J]. Ann Plast Surg, 2017, 78(3 Suppl 2):S83-S88. [17] 程亮亮, 田毅, 谭义文, 等. 右美托咪定通过PI3K/Akt/mTOR信号通路对肝叶切除术后神经认知功能障碍大鼠海马神经元自噬的影响[J]. 西部医学, 2021, 33(6):793-798,803. [18] Wang GB,Niu JH, Li ZT, et al. The efficacy and safety of dexmedetomidine in cardiac surgery patients: A systematic review and meta-analysis[J]. PLoS One, 2018, 13(9):e0202620. [19] Duncan D,Sankar A, Beattie WS, et al. Alpha-2 adrenergic agonists for the prevention of cardiac complications among adults undergoing surgery[J]. Cochrane Database Syst Rev, 2018, 3(3):CD004126. [20] Gu J, Chen J, Xia P, et al. Dexmedetomidine attenuates remote lung injury induced by renal ischemia-reperfusion in mice[J]. Acta Anaesthesiol Scand, 2011, 55(10):1272-1278. [21] Bao NR, Dai D. Dexmedetomidine protects against ischemia and reperfusion-induced kidney injury in rats[J]. Mediat Inflamm, 2020, 2020:2120971. [22] Yu XF, Chi XJ, Wu S,et al. Dexmedetomidine pretreatment attenuates kidney injury and oxidative stress during orthotopic autologous liver transplantation in rats[J]. Oxid Med Cell Longev, 2016, 2016:4675817. [23] Liu XR, Li T, Cao L,et al. Dexmedetomidine attenuates H2O2-induced neonatal rat cardiomyocytes apoptosis through mitochondria- and ER-medicated oxidative stress pathways[J]. Mol Med Rep, 2018, 17(5):7258-7264. [24] Fang MJ, He JB, Ma XY,et al. Protective effects of dexmedetomidine on the survival of random flaps[J]. Biomed Pharmacother, 2020, 128:110261. [25] Wang WZ,Baynosa RC, Zamboni WA. Update on ischemia-reperfusion injury for the plastic surgeon[J]. Plast Reconstr Surg, 2011, 128(6):685e-692e. [26] Fawzy MA, Maher SA, Bakkar SM, et al. Pantoprazole attenuates MAPK (ERK1/2, JNK, p38)-NF-κB and apoptosis signaling pathways after renal ischemia/reperfusion injury in rats[J]. Int J Mol Sci, 2021, 22(19):10669. [27] Zahra KF,Lefter R, Ali A, et al. The involvement of the oxidative stress status in cancer pathology: A double view on the role of the antioxidants[J]. Oxid Med Cell Longev, 2021, 2021: 9965916. [28] Uysal HY, Cuzdan SS, Kayıran O, et al. Preventive effect of dexmedetomidine in ischemia-reperfusion injury[J]. J Craniofac Surg, 2012, 23(5):1287-1291. [29] Fan X, Du J, Wang MH,et al. Irisin contributes to the hepatoprotection of dexmedetomidine during intestinal ischemia/reperfusion[J]. Oxid Med Cell Longev, 2019, 2019:7857082. [30] D'Amelio M, Cavallucci V, Cecconi F. Neuronal caspase-3 signaling: Not only cell death[J]. Cell Death Differ, 2010, 17(7):1104-1114. [31] Huang Q, Li F, Liu XJ,et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy[J]. Nat Med, 2011, 17(7):860-866. [32] Akgul C, Moulding DA, Edwards SW. Alternative splicing of Bcl-2-related genes: Functional consequences and potential therapeutic applications[J]. Cell Mol Life Sci, 2004, 61(17):2189-2199. [33] Siddiqui WA, Ahad A, Ahsan H. The mystery of BCL2 family: Bcl-2 proteins and apoptosis: An update[J]. Arch Toxicol, 2015, 89(3):289-317. [34] Chang JH, Jin MM, Liu JT.Dexmedetomidine pretreatment protects the heart against apoptosis in ischemia/reperfusion injury in diabetic rats by activating PI3K/Akt signaling in vivo and in vitro[J]. Biomed Pharmacother, 2020, 127:110188. [35] Xia P,Xu XY. PI3K/Akt/mTOR signaling pathway in cancer stem cells: From basic research to clinical application[J]. Am J Cancer Res, 2015, 5(5):1602-1609. [36] He L, Wang ZR, Zhou R,et al. Dexmedetomidine exerts cardioprotective effect through miR-146a-3p targeting IRAK1 and TRAF6 via inhibition of the NF-κB pathway[J]. Biomed Pharmacother, 2021, 133: 110993. [37] Riquelme JA, Westermeier F, Hall AR, et al. Dexmedetomidine protects the heart against ischemia-reperfusion injury by an endothelial ENOS/NO dependent mechanism[J]. Pharmacol Res, 2016, 103:318-327. [38] Wu ZL, Davis JRJ, Zhu Y.Dexmedetomidine protects against myocardial ischemia/reperfusion injury by ameliorating oxidative stress and cell apoptosis through the Trx1-dependent Akt pathway[J]. Biomed Res Int, 2020, 2020: 8979270. |